Saturday, 7 November 2026European Markets
Via News Knowledge File

U.S. Securities and Exchange Commission

government agency80% conf.·synced Nov 6, 2026

U.S. federal regulatory agency overseeing securities markets

0
sourced metrics
1720
relationships
8
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Stated objectives

Make the U.S. the crypto capital of the world

source
stated

Incorporate crypto into retirement programs through regulatory guidance

source
target: regulatory framework by 2026-01-01 00:00:00stated

Provide whistleblower rewards totaling up to 30% of any successful recovery for original information

source
target: 30 stated

Work toward allowing the inclusion of alternative assets in self-directed retirement plans

source
stated

Encourage whistleblowers to provide original information about securities violations through rewards program offering up to 30% of successful recoveries

source
target: 30 stated

SEC Whistleblower program incentivizing persons with non-public information about Hercules Capital securities violations to come forward with original information in exchange for monetary rewards

source
target: up to 30% of successful SEC enforcement recovery stated

Cut off opportunities for market manipulators to exploit small overseas IPO listings and protect mom-and-pop investors from pump-and-dump schemes.

source
stated

Establish dedicated crypto custody rules for registered investment advisors, funds and BDCs under federal securities law

source
stated

Relationship graph · 1720 connections

regulates
1445
regulated by
232
Employs
14
subsidiary of
5
Covered by
4
contracted by
4
files with
3
governs
2
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com